In addition to the bribery and corruption scandal, GlaxoSmithKline's troubles in China may extend to its Shanghai research and development facility that develops neurology treatments, a confidential document obtained by The New York Times suggests. An internal audit found that the drugmaker was exposed to possible regulatory action and financial risk after its executives were advised almost two years ago about crucial problems with its research practices at the facility. Some experts said these faults stress the problems that can come out when scientific development is exported by major drugmakers to China and other emerging markets.

Related Summaries